<?xml version='1.0' encoding='utf-8'?>
<document id="26800425"><sentence text="Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5." /><sentence text="Recent reviews suggest that chronic kidney disease (CKD) can affect the pharmacokinetics of nonrenally eliminated drugs, but the impact of CKD on individual elimination pathways has not been systematically evaluated" /><sentence text=" In this study we developed a comprehensive dataset of the effect of CKD on the pharmacokinetics of CYP2D6- and CYP3A4/5-metabolized drugs" /><sentence text=" Drugs for evaluation were selected based on clinical drug-drug interaction (CYP3A4/5 and CYP2D6) and pharmacogenetic (CYP2D6) studies" /><sentence text=" Information from dedicated CKD studies was available for 13 and 18 of the CYP2D6 and CYP3A4/5 model drugs, respectively" /><sentence text=" Analysis of these data suggested that CYP2D6-mediated clearance is generally decreased in parallel with the severity of CKD" /><sentence text=" There was no apparent relationship between the severity of CKD and CYP3A4/5-mediated clearance" /><sentence text=" The observed elimination-route dependency in CKD effects between CYP2D6 and CYP3A4/5 may inform the need to conduct clinical CKD studies with nonrenally eliminated drugs for optimal use of drugs in patients with CKD" /><sentence text="" /></document>